Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose-limiting toxicities Detailed clinical data for each program...
WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker...
—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— RESEARCH TRIANGLE PARK,...
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK, Nov....
Presented new CMP-001 data in melanoma at SITC’s 35th Anniversary Annual Meeting CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --...
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.,...
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new...
Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases Completed rebranding to...
Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT NEW YORK, Nov. 13, 2020...
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage...
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE...
—Data presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— RESEARCH TRIANGLE...
Results from the Phase 2 IMPERIAL study illustrate OC-01 nasal spray caused a decrease in goblet cell size, as compared...
TORONTO and HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a...
TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the...
Intertrade Shipping AS har i dag kjøpt 148 461 aksjer i Vistin Pharma ASA til gjennomsnittskurs 16,25 per aksje. Intertrade Shipping...
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage...
COPENHAGEN, Denmark, November 13, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) publishes corrected information about the following transactions...
– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian...